Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Timing of intravitreal triamcinolone with photodynamic therapy in AMD
2006-001386-42Phase 4Completed
- Sponsor
- Imperial College London
- Start
- May 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of triamcinolone acetonide in age-related macular degeneration (AMD) and Subretinal neovascularization, sponsored by Imperial College London. Primary endpoints: Visual acuity at 1 year and Lesion size at 1 year. Started May 2006; status: completed.
02
Drugs
triamcinolone acetonide
03
Conditions
age-related macular degeneration (AMD)Subretinal neovascularization
Beyond the preview
Go deeper on 2006-001386-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001386-42.